课题基金 / 基金详情

项目摘要

项目成果

IAN Michael MCGOWAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of Core D is to provide an infrastructure of regulatory and technical expertise to maintain and manage consistent compliance with the regulatory requirements for all projects in the PREVENT Program. The Core includes two separate but complementary components: (i) oversight of the preclinical work required to support a successful IND, including interactions with the FDA and (ii) management and oversight of regulatory compliance, training, and implementation of a pre-Phase 1 clinical trial. The Core will manage, track, develop, and provide coordinated responses to all regulatory submissions and Agency interactions. This will include the transition from pre-GMP to cGMP drug substance and drug product manufacture, pilot and GLP preclinical toxicology, strategic interactions with external regulatory agencies, and IND development and submissions, with a focus on regulatory training and education and the goal of standardizing the Program's regulatory practices. The Core will also provide an overall Quality Management Plan, and implement and monitor quality control and quality assurance activities, as needed, throughout all program projects and cores. The Core will coordinate and direct all required self-monitoring activities and will serve as a central document control repository.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 3: PREVENT: A first-in-human clinical trial of Griffithsin, an HIV entry
  • 批准号:
    8769380
  • 项目类别:
  • 资助金额:
    $44.26万
  • 财政年份:
    2014
  • 负责人:
    IAN Michael MCGOWAN
  • 依托单位:
Combination HIV Antiretroviral Rectal Microbicide Program
Combination HIV Antiretroviral Rectal Microbicide Program
Microbicide Safety and Acceptability in Young Men
国内基金
海外基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data